Across TCGA pan-cancer cohorts, ATP6AP1L Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP6AP1L data layer compared with 22 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher ATP6AP1L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP6AP1L expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCEC, and LUSC are the cancer types where ATP6AP1L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	1.000	0.627	.014	28	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	24	view →
ACC	DFS	Median	All	0.057	0.667	<.001	15	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ATP6AP1L tumor-vs-normal RNA expression · all ATP6AP1L data types